Abstract 4399
Background
Data on the efficacy and safety of all targeted therapies for metastatic renal cell carcinoma (mRCC) including sunitinib are collected in the Czech RENIS patient registry. RENIS thus provides a uniquely large sample of long-term effectiveness and prognostic data of sunitinib according to adverse/risk factors measured by the Memorial Sloan Kettering Cancer Center (MSKCC) score. The aim of this study was to analyze the long-term overall (OS) and progression-free survival (PFS) of sunitinib, when used as 1st line treatment, based on MSKCC risk group scores including MSKCC scores for two intermediate subgroups.
Methods
Data from mRCC patients treated using sunitinib in the 1st line were collected in RENIS between 06/2007 and 02/2018. OS/PFS were then stratified based on MSKCC scores: a) favorable risk (0 adverse factors (AF)), b) intermediate risk (pooled 1–2 AFs), and c) poor risk (3+ AFs). The OS/PFS of the intermediate risk group was further stratified into two subgroups: i) 1 AF and ii) 2 AFs. All OS/PFS data were analyzed using Kaplan-Meier estimates. Differences in OS/PFS between risk groups were assessed using median survival, 95% confidence intervals (CI), and the log-rank test. Then we assessed the OS/PFS for 1-, 3-, and 5-year survival.
Results
Over the 11-year follow-up, 2390 patients were treated using sunitinib with 806, 1450, and 134 patients in the favorable, intermediate, and poor MSKCC risk groups. The more favorable MSKCC risk group was accompanied by an improved OS and PFS (p < 0.001). Regarding the MSKCC for the two intermediate sub-groups, 1 AF was associated with improved survival compared to 2 AFs (p < 0.001) (Table).Table:
957P OS and PFS results for sunitinib treatment based on MSKCC risk groups
MSKCC favorable | MSKCC intermediate | MSKCC poor | MSKCC intermediate | All patients | ||
---|---|---|---|---|---|---|
1 AF | 2 AFs | |||||
Overall survival | ||||||
Median survival (95% CI) | 44.7months (40.9-50.5) | 24.1months (21.9-26.0) | 9.5months (7.2-14.1) | 28.2months (25.9-30.7) | 16.2months (14.5-20.2) | 28.5months (26.3-30.5) |
1-year survival (95% CI) | 85.0% (82.4-87.6) | 69.1% (66.6-71.7) | 44.3% (35.0-53.7) | 74.3% (71.4-77.2) | 58.0% (53.1-62.9) | 73.3% (71.4-75.2) |
3-year survival (95 %CI) | 57.3% (53.4-61.3) | 37.1% (34.1-40.1) | 9.6% (3.1-16.2) | 42.0% (38.3-45.7) | 26.3% (21.4-31.2) | 42.9% (40.5-45.2) |
5-year survival (95% CI) | 35.6% (31.2-40.1) | 23.4% (20.4-26.4) | 3.2% (0.0-8.8) | 26.5% (22.7-30.3) | 16.5% (11.8-21.2) | 26.8% (24.3-29.2) |
n | 806 | 1450 | 134 | 969 | 481 | 2390 |
Log-rank p-value | < 0.001 | < 0.001 | - | |||
Progression-free survival | ||||||
Median survival (95% CI) | 17.0months (15.4-18.8) | 9.0months (8.3-9.5) | 4.5months (3.9-6.1) | 10.1months (9.4-11.4) | 6.2months (5.5-7.5) | 10.6months (9.9-11.5) |
1-year survival (95% CI) | 61.8% (58.3-65.3) | 40.7% (38.0-43.4) | 20.8% (13.1-28.5) | 45.1% (41.8-48.4) | 31.6% (27.1-36.1) | 46.9% (44.7-49.0) |
3-year survival (95 %CI) | 25.1% (21.7-28.5) | 13.0% (11.0-15.1) | 1.8% (0.0-5.1) | 15.9% (13.2-18.6) | 7.0% (4.2-9.7) | 16.6% (14.9-18.4) |
5-year survival (95% CI) | 10.4% (7.7-13.2) | 8.0% (6.2-9.8) | 1.8% (0.0-5.1) | 9.7 (7.3-12.0) | 4.5% (2.1-6.9) | 8.4% (7.0-9.9) |
n | 806 | 1450 | 134 | 969 | 481 | 2390 |
Log-rank p-value | < 0.001 | < 0.001 | - |
Conclusions
Better MSKCC risk scores were associated with significantly longer OS and PFS. To our knowledge, this is the largest published sunitinib mRCC cohort described relative to MSKCC risk groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Finek: Honoraria (self): Amgen; Honoraria (self): BMS; Honoraria (self): Roche; Honoraria (self): Bayer; Honoraria (self): Teva; Honoraria (self): MSD; Honoraria (self): Merck; Honoraria (self): Sanofi; Honoraria (self): Pierre Fabre. A. Poprach: Honoraria (self): Pfizer; Honoraria (self): Roche; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): BMS; Honoraria (self): Bayer. B. Melichar: Honoraria (self): BMS; Honoraria (self): Merck; Honoraria (self): MSD; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Astellas Pharma; Honoraria (self): Pfizer; Honoraria (self): Bayer. J. Kopecky: Honoraria (self): BMS; Honoraria (self): Novartis; Honoraria (self): Pfizer. M. Zemanova: Advisory / Consultancy: Novartis; Honoraria (self): Eli Lilly; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Boehringer Ingelheim. T. Buchler: Honoraria (self): Amgen; Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: BMS; Advisory / Consultancy: Pfizer; Travel / Accommodation / Expenses: Janssen. K. Kopeckova: Honoraria (self): Novartis; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: Pfizer. T. Mlcoch: Full / Part-time employment: Value Outcomes. T. Dolezal: Full / Part-time employment: Value Outcomes. All other authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract